Abstract: A monitoring and control system, apparatus and method for safe administration, reduction or cessation of administration of at least on medication, fluid or both, which includes at least one Central Source Site (CSS) Photoplethysmography (PPG) sensor coupled to means for control of delivery of the at least one medication, fluid or both.

Abstract: A pharmacodynamic (PD), pharmacokinetic (PK), or both and PK guided infusion device, system and method optimizes the safety and efficacy of various forms of treatment or therapy (e.g., drug and/or fluid) in a variety of health-care and other settings.

Abstract: Novel compositions, methods, systems and devices are disclosed which contain markers for definitive medication adherence monitoring for Active Pharmaceutical Ingredients (APIs) delivered topically, vaginally or rectally. This invention is useful in a wide range of contexts, including, but not limited to, clinical trial settings, home use settings, or other settings, where it is necessary to definitively confirm that a given patient has taken or been administered a given medication at the correct time and in the correct dosage via a topical, vaginal or rectal route of delivery. Specific formulations of markers are disclosed for inclusion in compositions for Active Pharmaceutical Ingredient (API) delivery, including but not limited to delivery of microbicidally active compounds such that on topical, vaginal or rectal delivery, said AEM is detected in the breath or an Exhaled Drug Emplacement Marker, EDEM, which is a metabolite of the AEM, is detected in the breath.

Abstract: Solid Oral Dosage Forms (SODFs) comprising Self Monitoring and Reporting Therapeutics (SMART™) adherence technology are provided which require no or minimal modification of clinical trial materials (CTMs) or marketed drug while providing tamper resistant (literally foolproof) measurement of adherence that is highly accurate and without altering the chemical, manufacturing, and controls (CMC) of the CTM or marketed drug.

Abstract: A pharmacodynamic (PD), pharmacokinetic (PK), or both and PK guided infusion device, system and method optimizes the safety and efficacy of various forms of treatment or therapy (e.g., drug and/or fluid) in a variety of health-care and other settings.

Abstract: A monitoring and control system, apparatus and method for safe administration, reduction or cessation of administration of at least on medication, fluid or both, which includes at least one Central Source Site (CSS) Photoplethysmography (PPG) sensor coupled to means for control of delivery of the at least one medication, fluid or both.

Abstract: Provided according to embodiments of the present invention are methods of monitoring and treating respiratory depression that include securing a photoplethysmography (PPG) sensor to a central source site of an individual; administering a central nervous system (CNS) depressant to the individual; processing PPG signals front the PPG sensor with a computer in communication with the PPG sensor; and administering a narcotic reversal agent to the individual if the PPG signals or a physiological parameter derived therefrom are outside a preset value range. Related systems are also described.

Abstract: Systems and methods are provided for monitoring use of hand washing agents to determine compliance with hand hygiene guidelines. A hand washing agent is provided with a detectable, volatile compound, such as odors, which is then rubbed onto a subject's hands using the subject's hand washing technique. After the hand washing event, the subject's hand is then exposed to an detector (such as a badge), which includes a sensor capable of detecting the volatile compound, and an indicator that communicates detection of the volatile compound, indicating use of the hand washing agent and hand hygiene compliance.

Abstract: The present invention provides systems and methods for analyzing glucose present in exhaled breath condensate (EBC). In certain embodiments of the invention, electrochemical- or coulometric-based sensing technologies are used to analyze EBC for the presence and/or concentration of glucose.

Abstract: Systems and methods are provided for monitoring use of hand washing agents to determine compliance with hand hygiene guidelines. A hand washing agent is provided with a detectable, volatile compound, such as odors, which is then rubbed onto a subject's hands using the subject's hand washing technique. After the hand washing event, the subject's hand is then exposed to an detector (such as a badge), which includes a sensor capable of detecting the volatile compound, and an indicator that communicates detection of the volatile compound, indicating use of the hand washing agent and hand hygiene compliance.

Abstract: Systems and methods are provided for monitoring use of hand washing agents to determine compliance with hand hygiene guidelines. A hand washing agent is provided with a detectable, volatile compound, such as odors, which is then rubbed onto a subject's hands using the subject's hand washing technique. After the hand washing event, the subject's hand is then exposed to an detector (such as a badge), which includes a sensor capable of detecting the volatile compound, and an indicator that communicates detection of the volatile compound, indicating use of the hand washing agent and hand hygiene compliance.

Abstract: A method of removing a toxic compound comprising contacting the toxic compound with a particle having two regions, the first region containing a detoxifying enzyme and the second region containing a material selected to partition the toxic compound into the second region. The particle may be a nanoparticle.

Abstract: The present invention provides systems and methods for determining enzymatic competency, which is important in determining whether a patient may suffer an adverse drug reaction, has a disease associated with defects in specific enzymatic function, and/or has an enzyme defect that is likely to cause pathophysiology. As contemplated herein, a parent molecular entity is administered to a patient in whom enzymatic competency is to be determined. A sample of the patient's bodily fluid is exposed to a sensor of the invention to distinguish, detect, and quantify a detectable entity in the bodily fluid. Sensor-acquired data regarding the detectable entity is used to determine enzymatic competency. Preferably, a sample of a patient's exhaled breath is collected and exposed to the sensor of the invention.

Abstract: Systems and methods are provided for monitoring use of hand washing agents to determine compliance with hand hygiene guidelines. A hand washing agent is provided with a detectable, volatile compound, such as odors, which is then rubbed onto a subject's hands using the subject's hand washing technique. After the hand washing event, the subject's hand is then exposed to an detector (such as a badge), which includes a sensor capable of detecting the volatile compound, and an indicator that communicates detection of the volatile compound, indicating use of the hand washing agent and hand hygiene compliance.

Abstract: The subject invention pertains to methods of treating mental illnesses or conditions characterized by a decreased function of NMDA receptors and/or excessively enhanced glutamate release and activity of non-NMDA receptors (AMPA and/or kainate). Specifically disclosed are methods utilizing BrPhe, or isomers of analogs thereof, for treating or preventing mental illness or conditions such as schizophrenia.

Abstract: The present invention provides systems and methods for analyzing glucose present in exhaled breath condensate (EBC). In certain embodiments of the invention, electrochemical- or coulometric-based sensing technologies are used to analyze EBC for the presence and/or concentration of glucose.

Abstract: The subject invention provides microemulsions having, as one component thereof, electron-deficient aromatic rings, e.g.. di(trifluoromethyi) benzene, for efficient separation and/or isolation of target molecules, e.g., bupivacaine.

Abstract: The invention relates to the nanotubes of various sizes and composed of a wide variety of materials, or combination of materials. The invention also describes the use of such nanotubes for the delivery of various payloads and, in particular, for the in vivo delivery of bioactive substances.

Abstract: A particle with two regions, the first region contains a detoxifying enzyme and a second region that partitions toxic compounds. The particle may be a nanoparticle.

Abstract: A microemulsion delivery system for water insoluble or sparingly water soluble drugs that comprises a long polymer chain surfactant component and a short fatty acid surfactant component, with the amount of each being selected to provide stable microemulsion or micellar systems.